LONDON, June 5 (Reuters) - Doctors in Europe can continue to use Sanofi-Aventis SA's heparin medicine Lovenox, despite low levels of contamination found in some batches of the product, the European ...

Paris, France - Enoxaparin (Lovenox, Sanofi-Aventis) seems to be associated with a lower risk of cardiovascular outcomes compared with unfractionated heparin (UFH) in patients with STEMI undergoing ...

The authors looked only at TIMI 11B patients for whom data on aPTT had been collected (n=1893) and compared the number of events and bleeding rates after 48 hours in patients on UFH to patients who ...

Lovenox (enoxaparin) is a prescription drug used to prevent or treat certain types of blood clots. Lovenox’s cost may depend on factors such as your dosage, whether you have health insurance, and how ...

Shares of Momenta took a hit after the company warned that its development of a generic version of Sanofi's blood thinner Lovenox is likely to take longer than expected. Shares slid 15 percent on the ...

Techdow USA is introducing 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg and 150 mg strengths of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, which is the generic of Sanofi-Aventis’ ...

You know those movie scenes in which our hero is moving downriver in a boat, only to suddenly happen upon an enormous waterfall? We have to watch while the hero frantically paddles upstream or makes ...

(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding ...

Paris, France - Aug 26, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. District Court for the District of Columbia has denied the Company's request for preliminary ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on the U.S. Food and Drug Administration’s response to a citizen petition questioning the approval ...

SAN FRANCISCO (MarketWatch) -- Sanofi-Aventis on Wednesday said the Food and Drug Administration has accepted for review a supplemental new drug application for its Lovenox anticoagulant for the ...